|
 |
 |
 |
 |
|
 |
|
|
|
|
Definitions:
This document outlines the
Roche product
development portfolio
as of
17-APR-08
including new molecular
entities and major
line extensions. The portfolio will change with time as compounds enter from research,
progress through to the next phase of development or enter the market place. The
high risk nature of the drug development process also means that it is not unusual for
some projects to be terminated if they do not meet the criteria for progression and this
will be particularly true in the early stages.
|
|
|
Definitions:
Phase 1: Phase 1
is defined
as the stage of development
where safety studies are initiated and the drug first enter humans.
Phase
2: This phase of development represents the first trials of study efficacy of the compound
in
humans.
Phase 3: This represents the larger clinical
trial usually involving
a comparision against a standard comparator compound in preparation for the registration of the compound
and approval by regulatory authorities.
|
|
|
|
|
|
|
|
|
print this page